Background
Patients with glioblastoma face a grim prognosis. Despite recent advancement in neurosurgical technology and neuro-oncology glioblastomas almost invariably progress or recur.Learn more about the trial
Objectives
The primary objective of this trial is to compare survival outcome after surgery followed by adjuvant second-line therapy to no surgery followed by second-line therapy in recurrent glioblastoma.Learn more about the trial
Latest News
Keep track on the Trial processExpanding across Europe!
Since early 2025, the Resurge Trial has significantly expanded its European presence. We’re thrilled to announce NEW additions complementing our already active sites: This growth strengthens our ability to engage[…]
Read moreThank you!
The ReSurge trial could achieve an increasing recruitment rate during the last year. This is great, especially in view of the pandemia which accompanies us for over a year now.[…]
Read moreNew patients in
Also the newly opened sites in Larisa, Erfurt and Mainz could recuit their first patient. Moreover, one more patient was recruited in Lausanne and six in Bern.In total 36 patients[…]
Read more